May 11 – 15, 2026 | Boston, MA, USA

StageBio is excited to attend the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting in Boston, Massachusetts this May. Our team will be on-site and ready to connect with you to discuss how we can support your cell and gene therapy development programs. Whether you're advancing early discovery, IND-enabling studies, or late-stage development, we're here to explore how our scientific expertise and specialized pathology services can help drive your programs forward.

As one of the most comprehensive cell and gene therapy events in the world, ASGCT brings together leading researchers, developers, and industry partners to advance the science and translation of transformative therapies. Come find our team and learn how StageBio's collaborative approach to pathology delivers the precision, quality, and regulatory confidence sponsors need to bring safe and effective cell and gene therapies to market.

StageBio's Expertise in Cell and Gene Therapy Pathology

StageBio provides comprehensive pathology services to support cell and gene therapy development programs. Our capabilities include:

• Pathology Expertise: 20+ pathologists working across sites, providing specialized expertise in therapeutic modalities including cell and gene therapy, biologics, and immuno-oncology, as well as organ systems such as the nervous, immune, and ocular systems. Deliverables include reports, peer reviews, consulting, and tailored support for complex client needs.

• Toxicologic Pathology: Significant experience in both GLP and non-GLP studies across all major species, with expertise in reporting, study design, and peer review to support IND-enabling and late-stage development programs.

• Specialized Histology Expertise: High-quality, reproducible histology supported by advanced capabilities including IHC/IF assay development, custom biomarker validation, and precision histotechnology workflows designed for the unique demands of cell and gene therapy studies.

Whether you're developing a viral vector, gene editing platform, CAR-T therapy, or other advanced modality, our team brings the proven expertise and regulatory insight needed to advance your program with confidence.

Meet Our Team

Lisa Mangus, DVM, PhD, DACVP, DABT Veterinary Pathologist, Neuropathology Lisa Mangus is a Senior Pathologist at StageBio with 10 years of experience supporting translational research and preclinical drug development. Board-certified in veterinary pathology and toxicology, she specializes in neuropathology with a focus on the central and peripheral nervous systems. Lisa brings a collaborative, detail-oriented approach to complex studies, leveraging StageBio's advanced histotechnology capabilities to deliver precise, high-quality results for clients developing novel therapeutics.

Anthony Rohr Business Development Executive Anthony Rohr is a Business Development Executive at StageBio with more than two decades of experience in contract research and development. With a background spanning CRO operations, regulatory frameworks, and commercial strategy, he helps clients navigate complex preclinical workflows with confidence. Known for a consultative, efficiency-driven approach, Anthony supports scalable growth and strong client partnerships.

Connect With Us

Find us on the floor at ASGCT 2026 to discuss your pathology needs, explore partnership opportunities, or simply connect with our team. We look forward to seeing you in Boston!